Inmunoterapia: Nuevo paradigma en el tratamiento del cáncer de pulmón microcítico

32 / 62

Nivolumab
(n = 284)
Chemotherapy
(n = 285)
No. of events 258 235
Median PFS 1.4 3.8
(95% CI), mo (1.4–1.5) (3.0–4.2)
HR (95% CI) 1.41 (1.18–1.69)
PFS a
32
aPer local investigator
17
13
284
285
74
136
50
62
37
34
27
22
21
14
15
11
11
6
8
2
2
1
1
0
0
0
12-mo PFS = 11%
12-mo PFS = 10%
6-mo PFS = 20%
6-mo PFS = 26%
Nivolumab
Chemotherapy
0 3 6 9 12 15 18 21 24 27 30 33 36
0
40
60
80
100
PFS (%)
Months
20
No. at risk
Nivolumab
Chemo